Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca B Regulatory News (SVCT)

Share Price Information for Seneca B (SVCT)

Share Price is delayed by 15 minutes
Get Live Data
44.00    0.00 (0.00%)
Bid:
43.00
Ask:
45.00
Spread: 2.00 (4.651%)
Market Cap: £14.56m
SVCT Live PriceLast checked at - London Stock Exchange

Intraday Seneca B Share Chart

Updated NAV & Ordinary Share Class Dividend

15 Oct 2025 16:26

RNS Number : 5441D
Seneca Growth Capital VCT PLC
15 October 2025
 

Updated Net Asset Values and Ordinary Share Class Dividend Declaration

Seneca Growth Capital VCT Plc 

15 October 2025

 

Seneca Growth Capital VCT Plc

Unaudited Net Asset Value ("NAV") Update as at 30 September 2025

The Directors of Seneca Growth Capital VCT Plc (the "Company") and the Investment Manager of the Company, Seneca Partners Limited ("Seneca"), have reviewed the valuation of the Company's investment portfolios for the quarter ending 30 September 2025 and announce an updated NAV for each of the Company's Ordinary and B share classes as at 30 September 2025.

For the purposes of calculating the NAV per share for both share classes, quoted investments are valued in line with closing bid prices as at 30 September 2025 and unquoted investments are carried at fair value.

B share NAV as at 30 September 2025

As at 30 September 2025, the unaudited B share NAV was 47.7p per share, a 2% decrease from the previously published unaudited NAV as at 30 June 2025 of 48.7p.

The B share NAV Total Return was 67.2p compared to 68.2p as at 30 June 2025.

The 1.0p decrease in NAV per B share in the quarter is principally due to movements in the share prices of the B share pool's AIM/AQSE quoted investee companies during the quarter.

Ordinary share NAV as at 30 September 2025

As at 30 September 2025, the unaudited Ordinary share NAV was 13.1p per share, a 16% increase from the previously published unaudited NAV as at 30 June 2025 of 11.3p.

The Ordinary share NAV Total Return was 89.4p compared to 87.6p as at 30 June 2025.

The 1.8p increase in NAV per Ordinary share is principally due to the increase in the share price of AIM quoted Arecor Therapeutics Plc ("Arecor") and Scancell Holdings Plc ("Scancell").

Scancell was the largest holding in the Ordinary share portfolio, representing 92% of the Ordinary share NAV as at 30 June 2025. As a result, the Ordinary share NAV moved largely in line with the movement in the Scancell share price during the quarter. The Company was presented with an opportunity to de-risk the concentration of the holding for Ordinary shareholders and was able to achieve a profitable exit of c.47% of the Ordinary share pool's holding as at 30 June 2025. Seneca was able to realise £435k in proceeds from the disposal, which generated a profit of £172k, resulting in an average weighted return of 1.7x on original investment cost. This disposal has enabled the Company to declare a second interim capital dividend of 5.0p per Ordinary share.

The Ordinary share pool's unquoted investments have all previously been written down to £nil carrying value. The valuations of the Ordinary share pool's unquoted investments remain unchanged as at the quarter end.

Second Interim Capital Dividend on Ordinary Shares

The Directors of the Company are pleased to declare an interim capital dividend of 5.0 pence per Ordinary Share for the year to 31 December 2025, to be paid on 7 November 2025.

The ex-dividend date is 23 October 2025.

The record date for the dividend is 24 October 2025.

The dividend payment date is 7 November 2025.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this information is now considered to be in the public domain.

For further information, please contact:

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Siobhan Pycroft, Seneca Partners Limited at Siobhan.Pycroft@senecapartners.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVPKPBBPBDDBKD
Date   Source Headline
28th Apr 202110:52 amGNWIssue of Equity and Total Voting Rights
1st Apr 20215:29 pmGNWDirector/PDMR Shareholding
1st Apr 202111:36 amGNWIssue of Equity and TVR
31st Mar 20217:00 amGNWNet Asset Value(s)
29th Mar 20215:12 pmGNWResult of AGM
4th Mar 20215:26 pmGNWDirector/PDMR Shareholding
2nd Mar 202112:50 pmGNWIssue of Equity and Total Voting Rights
24th Feb 20211:49 pmGNWIssue of Prospectus
23rd Feb 20217:00 amGNWFinal Results and NAV Update
18th Feb 20217:00 amGNWDividend Declaration
10th Dec 20203:57 pmGNWDirector/PDMR Shareholding
9th Dec 20203:49 pmGNWIssue of Equity and Total Voting Rights
5th Nov 20207:00 amGNWDividend Declaration
13th Oct 20204:22 pmGNWOffer for Subscription
5th Oct 20207:00 amGNWSecond Interim Capital Dividend
5th Oct 20207:00 amGNWNAV Update
16th Sep 20207:00 amGNWInvestment Realisations and NAV
21st Aug 202010:55 amGNWChange of Registered Office
30th Jul 20207:00 amGNWHalf-year report
10th Jul 202011:43 amGNWIssue of Equity
24th Jun 202012:35 pmGNWB Share - Extension of Offer
13th May 20203:03 pmGNWPublication of a supplementary prospectus
29th Apr 202012:45 pmGNWIssue of Equity
29th Apr 20207:00 amGNWResult of Annual General Meeting
27th Apr 20206:52 pmGNWUpdate on Omega, Optibiotix and NAVs
20th Apr 20206:36 pmGNWOmega Diagnostics, Net Asset Value, New B Share Pool Investments
7th Apr 20204:35 pmGNWIssue of Supplementary Prospectus
3rd Apr 20202:10 pmGNWIssue of Equity
31st Mar 20205:30 pmGNWNet Asset Value(s)
26th Mar 20204:31 pmGNWAGM Venue Change
13th Mar 20204:14 pmGNWInterim Dividend
10th Mar 20202:28 pmGNWIssue of Equity
10th Mar 20207:00 amGNWB Share Net Asset Value
3rd Mar 20204:30 pmGNWIssue of Supplementary Prospectus
27th Feb 20207:00 amGNWFinal Results
9th Dec 20195:45 pmGNWDirectorate Change
27th Nov 20192:45 pmGNWIssue of Equity
20th Nov 20194:00 pmGNWDuplicate: Second Interim Dividend
28th Oct 20197:00 amGNWSecond interim dividend
10th Oct 20196:30 pmGNWDirector/PDMR Shareholding
10th Jun 20196:14 pmRNSResult of AGM
16th May 20197:00 amRNSSecond Interim Dividend
29th Apr 20198:52 amRNSFinal Results
25th Apr 20197:00 amRNSNet Asset Value(s)
5th Apr 201912:47 pmRNSIssue of Equity
3rd Apr 201912:46 pmRNSIssue of Equity
29th Mar 20195:20 pmRNSRevised timetable
13th Mar 201912:03 pmRNSExtension of Offer
7th Mar 20193:22 pmRNSIssue of Equity
6th Mar 201910:30 amRNSInterim Dividend

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.